Tekmira Pharmaceuticals this week announced that it has signed a deal giving ag-bio firm Monsanto the option to license its proprietary lipid-based RNAi delivery technology for use in agricultural applications.

Over the four-year term of the option, Tekmira will provide Monsanto with lipid formulations in exchange for undisclosed payments to maintain the option. If Monsanto choses to exercise its option, it will pay an undisclosed fee to Tekmira and receive an exclusive, worldwide license to its delivery technology in agriculture.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: phylogenetic study of hepatitis E viruses in Swedish moose, recombination sites in the honeybee genome, and more.

Differences in DNA methylation could be used to distinguish between DNA samples obtained from identical twins, researchers say.

A retrovirus that's been integrated into the human genome appears to have a role in embryonic development, researchers report.

A report from MIT identifies areas of scientific research where declining research support is hindering needed advances.